Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & EMBASE  
     Home | Subscribe | Feedback  

[Download PDF
Year : 1995  |  Volume : 41  |  Issue : 3  |  Page : 64-5  

Roxatidine in duodenal ulcer.

CM Habibullah, MA Habeeb, SP Singh 
 Dept of Gastroenterology, Osmania Medical College, Osmania General Hospital, Hyderabad.

Correspondence Address:
C M Habibullah
Dept of Gastroenterology, Osmania Medical College, Osmania General Hospital, Hyderabad.


Roxatidine acetate is a new H2-receptor antagonist. A randomized double-blind clinical trial in fifty-three patients with endoscopically proven duodenal ulcers > 5 mm in diameter was undertaken to compare safety and efficacy of roxatidine with that of ranitidine. Twenty-six patients received roxatidine (75 mg bid) while 27 patients received ranitidine (150 mg bid) for 4 weeks. One patient in each group did not come for follow up. Roxatidine and ranitidine had comparable ulcer healing rates (22/25 vs 22/26); roxatidine, however, resulted in greater reduction in the number and severity of night time pain episodes (p < 0.05). No adverse event was reported during 4 weeks of treatment with roxatidine. Thus roxatidine achieves the primary therapeutic goal of relief of pain better than ranitidine.

How to cite this article:
Habibullah C M, Habeeb M A, Singh S P. Roxatidine in duodenal ulcer. J Postgrad Med 1995;41:64-5

How to cite this URL:
Habibullah C M, Habeeb M A, Singh S P. Roxatidine in duodenal ulcer. J Postgrad Med [serial online] 1995 [cited 2022 May 26 ];41:64-5
Available from:

Full Text

  ::   IntroductionTop

H2receptor antagonists are now the most widely used therapeutic agents in the treatment of peptic ulcers. The main stay of therapy for peptic ulcers is inhibition of gastric acid secretion. This requisite has to be fulfilled effectively by all H2 receptor antagonists. However, one of the primary therapeutic goals in such patients is relief of pain and it is in this aspect that further improvement is possible in the therapeutic efficacy of newer H2receptor antagonists[1].

Roxatidine acetate is a new H2receptor antagonist with a novel chemical structure. It is a piperidine derivative unlike cimetidine, ranitidine and famotidine, which are imidazole, furan and thiazole derivatives, respectively[2]. It is well tolerated in healthy volunteers in single[3] as well as multiple[4] doses. It effectively inhibits both daytime and nighttime secretion of gastric acid[5] and has been shown to be twice as potent as ranitidine in inhibiting gastric acid production[6].

The present study was undertaken to compare the safety and efficacy of roxatidine acetate with that of ranitidine in duodenal ulcers in an Indian population.

  ::   MethodsTop

The study was a randomised, doubleblind trial (using a double dummy technique) comparing roxatidine (75 mg bid) with ranitidine (150 mg bid) given for 4 weeks. The Ethics Committee of the hospital approved the study protocol. Patients with endoscopically confirmed uncomplicated duodenal ulcers, either solitary or multiple with a minimum diameter of 5 mm. were enrolled in the study. A detailed clinical history was taken and thorough examination undertaken.

Pregnant women, lactating mothers patients having ZollingerEllison syndrome malignancy or complications of duodenal ulcer viz bleeding stricture obstruction and perforation and those with evidence or renal, hepatic, cardiac, respiratory, hematological or bleeding disorders were excluded from the study. Informed written consent was obtained from each patient. Endoscopy was done within 3 days of enrolment into the study and at the end of 4 weeks. The site, size and number of ulcers were recorded. Ulcer healing on endoscopy was assessed as complete healing, improvement unchanged or aggravated.

Pain relief was assessed in 2 ways: a) daily diary: patients were instructed to keep a daily record of number and severity of day and nighttime pain episodes; and b) Weekly followup visits: patients were asked whether pain relief was 25%, 50%, 75% or 100% as compared to the previous visit.

All patients were subjected to laboratory investigations (leucocyte count, ESR. Serum bilirubin, Serum Creatinine, BUN, Fasting blood sugar. SGOT, SGPT and routine urinalysis), before and after treatment. A careful watch was kept for any adverse event at every follow up visit.

Statistical Analysis: The statistical tests used for inter-group comparisons were the test, Wilcoxon's rank sum test, Fisher's exact probability test and analysis of covariance.

  ::   ResultsTop

Fiftythree patients with duodenal ulcer were randomised to the roxatidine group (24 men, 2 women; aged 38.0 + 3.0 yr) and the ranitidine group (24 men, 3 women aged 38.0 + 2.7 yr). Both groups had long standing ulcers, ranging from 15 yr. There was no significant difference in the demographic data, clinical profile or patients in the two treatment groups. All 53 patients had solitary duodenal ulcers, the mean size being 8.6 mm and 9.8 mm in the roxatidine and ranitidine groups respectively. One patient each in the two groups failed to report for followup: these patients were excluded from the analysis.

Pain relief, assessed at weekly follow up, was similar in the two treatment groups. Data collected through the selfassessment diaries were analysed for the number of episodes and severity of daytime and nighttime pain [Table:1]. The decline in the number and severity score of daytime pain episodes was comparable in the two groups, at the end of 4 weeks. However the roxatidine group showed higher percentage reduction in the number (93.8% vs 75.3%; p < 0.05) and severity scores (97.1 % vs 85.5%; p < 0. 05) of nighttime pain episodes. The reduction in pain from the baseline values was tested by analysis of covariance with baseline values as covariates.

At 4 weeks, endoscopy showed complete ulcer 6. healing in 22125 (88%) patients on roxatidine and 22/26 (84.6%) patients on ranitidine (p = ns). Three patients in each group had partial healing. One patient failed to respond to ranitidine while none in the roxatidine group showed any failure of healing. None of the patients in either group had adverse event.

  ::   DiscussionTop

Our study shows that roxatidine 75 mg twice a day and ranitidine 150 mg twice a day for 4 weeks resulted in comparable duodenal ulcer healing. However, patients on roxatidine showed a significantly greater reduction in the number and severity of night-time pain episodes, as compared to ranitidine.

Our findings are similar to those of several other clinical trials from Europe, Japan and USA which show that roxatidine is comparable to other H2 receptor antagonists in terms of cumulative healing rates[6], The superior nighttime pain relief that we observed with roxatidine is particularly important from the patient's point of view.

The present study also shows that roxatidine is welltolerated by Indian patients, with no patient reporting any adverse event during 4 weeks of treatment.

  ::   AcknowledgmentTop

We thank the Superintendent, Osmania General Hospital for allowing us to carry out the study and Hoechst India Limited for providing the study material and medications for the trial.


1 Dammann HG, Dreyer M, Kangah R, Muller P, Simon B. Optimal reduction of gastric acid secretion in the treatment of peptic ulceration. Drugs 1988; 35:106113.
2Dammann HG. Clinical characteristics of roxatidine acetate: a review. Scand J Gastroenterol 1988; 23:121134.
3Hagenmuller F, Webber C, Hausamann S. The effects of 75 mg HOE 760, a novel H2 receptor antagonist, on day time peptone stimulated nocturnal gastric acid output in healthy volunteers. Scand J Gastroenterol 1987; 22:609614.
4Hasegawa X, Osawa H, Mine T. Phase I study on TZU-0460 a novel histamine H2 receptor antagonist. 7 and 56 consecutive day study. Jpn Pharmacol Ther 1985; 12:187195.
5Ueno K, Anagaya T, Sato J, Ishikawa M. Effect of new H2receptor antagonist TZU0460 on intragastric acidity Jpn Pharmacol Ther 1985; 13:579587.
6Merki HS, Bender W, Labs R. Safety and efficacy of roxatidine acetate. Gastroenterol 1989; 11:520523.

Thursday, May 26, 2022
 Site Map | Home | Contact Us | Feedback | Copyright  and disclaimer